Prime Only Members-Only Article

Spend the Money

|
May 17, 2022 5:11 p.m.

Some of you likely have had similar experiences or know people who have. I continue to hear from people who got COVID, got fairly sick, then took the main antiviral, Paxlovid, and basically within a day or so went from bad flu to mild cold at worst. I just heard another story like this from a reader. To be clear, these weren’t people who were hospitalized. But the people who I’m talking about were, either because of age or health conditions, people who had heightened vulnerability to COVID. They were getting sick and then they got almost totally better very quickly. Probably most or all of them would have been fine. And in many cases they were just saved a miserable week or two. But as we know, a bad case of COVID can degenerate quickly.

Real Independence
Made Possible By Members

FREE community-supported memberships are available to students and those experiencing financial hardship

Most Popular
Prime
$60/yr
$60/yr
30% off!
Access to Member-Exclusives and Fewer Ads
Get Prime

    Also Includes:

  • The Hive Member Forum
  • Members-Only Newsletter
  • RSS Feeds
  • Commenting
Prime
$5.99/mo
Access to Member-Exclusives and Fewer Ads
Get Prime

    Also Includes:

  • The Hive Member Forum
  • Members-Only Newsletter
  • RSS Feeds
  • Commenting
Prime Ad Free
$120/yr
Access to Member-Exclusives and NO Ads
Get Prime AF

    Also Includes:

  • The Hive Member Forum
  • Members-Only Newsletter
  • RSS Feeds
  • Commenting
Prime Ad Free
$11.99/mo
Access to Member-Exclusives and NO Ads
Get Prime AF

    Also Includes:

  • The Hive Member Forum
  • Members-Only Newsletter
  • RSS Feeds
  • Commenting
Annual Plans
Monthly Plans

More Membership Options

Student (free with .edu email) CREATE STUDENT ACCOUNT Community-Supported (free all-access membership) APPLY NOW TPM Inside LEARN MORE
CONTACT FAQ
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Associate Editor:
Investigations Desk:
Reporters:
Newswriters:
Director of Audience:
Editor at Large:
General Counsel:
Publisher:
Head of Product:
Director of Technology:
Associate Publisher:
Front End Developer:
Senior Designer: